Chembio Diagnostics, Inc. (CEMI): Price and Financial Metrics

Chembio Diagnostics, Inc. (CEMI): $0.65

-0.03 (-3.75%)

POWR Rating

Component Grades














  • CEMI scores best on the Value dimension, with a Value rank ahead of 67.65% of US stocks.
  • CEMI's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • CEMI's current lowest rank is in the Sentiment metric (where it is better than 1.9% of US stocks).

CEMI Stock Summary

  • CEMI has a higher market value than only 4.65% of US stocks; more precisely, its current market capitalization is $25,879,016.
  • The volatility of Chembio Diagnostics Inc's share price is greater than that of 94.71% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CEMI comes in at -150.07% -- higher than that of only 2.17% of stocks in our set.
  • Stocks that are quantitatively similar to CEMI, based on their financial statements, market capitalization, and price volatility, are ACIW, MKSI, MASS, CPSI, and LIVN.
  • CEMI's SEC filings can be seen here. And to visit Chembio Diagnostics Inc's official web site, go to

CEMI Valuation Summary

  • CEMI's price/earnings ratio is -3; this is 108.22% lower than that of the median Healthcare stock.
  • Over the past 209 months, CEMI's price/sales ratio has gone down 1.3.
  • Over the past 209 months, CEMI's price/earnings ratio has gone up 1.8.

Below are key valuation metrics over time for CEMI.

Stock Date P/S P/B P/E EV/EBIT
CEMI 2021-08-31 2.2 5.2 -3.0 -4.2
CEMI 2021-08-30 2.3 5.3 -3.1 -4.3
CEMI 2021-08-27 2.4 5.7 -3.3 -4.5
CEMI 2021-08-26 2.2 5.1 -2.9 -4.1
CEMI 2021-08-25 2.2 5.1 -3.0 -4.1
CEMI 2021-08-24 2.1 5.0 -2.9 -4.1

CEMI Growth Metrics

    Its 4 year revenue growth rate is now at 34.1%.
  • Its 4 year net income to common stockholders growth rate is now at -672.13%.
  • The 5 year price growth rate now stands at 63.99%.
Over the past 34 months, CEMI's revenue has gone up $13,825,367.

The table below shows CEMI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 47.81845 -30.88572 -33.90353
2021-09-30 37.47188 -28.89083 -27.06958
2021-06-30 35.68591 -27.46491 -26.24253
2021-03-31 34.33497 -20.49654 -25.02194
2020-12-31 32.4702 -18.88724 -25.52133
2020-09-30 29.09398 -16.80419 -22.27106

CEMI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CEMI has a Quality Grade of F, ranking ahead of 4.04% of graded US stocks.
  • CEMI's asset turnover comes in at 0.59 -- ranking 57th of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and ENDP are the stocks whose asset turnover ratios are most correlated with CEMI.

The table below shows CEMI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.590 0.400 -0.488
2021-03-31 0.508 0.329 -0.488
2020-12-31 0.492 0.265 -0.504
2020-09-30 0.457 0.251 -0.430
2020-06-30 0.472 0.265 -0.404
2020-03-31 0.642 0.334 -0.343

CEMI Price Target

For more insight on analysts targets of CEMI, see our CEMI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.00 Average Broker Recommendation 1.83 (Hold)

CEMI Stock Price Chart Interactive Chart >

Price chart for CEMI

CEMI Price/Volume Stats

Current price $0.65 52-week high $7.34
Prev. close $0.68 52-week low $0.42
Day low $0.65 Volume 227,600
Day high $0.70 Avg. volume 316,441
50-day MA $0.65 Dividend yield N/A
200-day MA $1.34 Market Cap 19.64M

Chembio Diagnostics, Inc. (CEMI) Company Bio

Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.

CEMI Latest News Stream

Event/Time News Detail
Loading, please wait...

CEMI Latest Social Stream

Loading social stream, please wait...

View Full CEMI Social Stream

Latest CEMI News From Around the Web

Below are the latest news stories about Chembio Diagnostics Inc that investors may wish to consider to help them evaluate CEMI as an investment opportunity.

Colliers Securities Reiterates Their Hold Rating on Chembio Diagnostics (CEMI)

Colliers Securities analyst Kyle Bauser reiterated a Hold rating on Chembio Diagnostics (CEMI – Research Report) today. The company's shares closed last Thursday at $0.92, close to its 52-week low of $0.80. According to, Bauser has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.8% and a 35.1% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Semler Scientific, and Impedimed Limited. The word on The Street in general, suggests a Hold analyst consensus rating for Chembio Diagnostics.

Howard Kim on TipRanks | March 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | March 4, 2022

Why Chembio Diagnostics Shares Are Falling

Chembio Diagnostics Inc (NASDAQ: CEMI ) shares are trading lower by 12.4% at $0.81 after the company reported worse-than-expected fourth-quarter adjusted EPS results. Chembio Diagnostics reported quarterly losses of 32 cents per share which missed the analyst consensus estimate of a loss of 20 cents per share by 60 percent. Chembio Diagnostics also reported quarterly sales of $20.57 million which beat the analyst consensus estimate of $13.55 million by 52%. This sales figure represents a 101% increase over … Full story available on

Benzinga | March 4, 2022

Despite More Than Double Q4 Sales, Chembio Diagnostics Posts Deeper Losses

Chembio Diagnostics Inc''s (NASDAQ: CEMI ) Q4 sales increased 101% Y/Y to $20.6 million , beating the consensus of $13.55 million. Net product sales increased 154% to $17.4 million. Government grant, license, and royalty, and R&D revenue totaled $3.2 million, down 6%. Chembio posted a wider operating loss of $(13.97) million, compared to $(7.14) million a … Full story available on

Benzinga | March 4, 2022

Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | March 3, 2022

Read More 'CEMI' Stories Here

CEMI Price Returns

1-mo -3.65%
3-mo -24.46%
6-mo -40.37%
1-year -79.37%
3-year -89.33%
5-year -89.34%
YTD -42.98%
2021 -76.00%
2020 4.17%
2019 -19.43%
2018 -30.98%
2017 20.59%

Continue Researching CEMI

Want to see what other sources are saying about Chembio Diagnostics Inc's financials and stock price? Try the links below:

Chembio Diagnostics Inc (CEMI) Stock Price | Nasdaq
Chembio Diagnostics Inc (CEMI) Stock Quote, History and News - Yahoo Finance
Chembio Diagnostics Inc (CEMI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6382 seconds.